Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-22), Abbott Laboratories's 3-1 Month Momentum % is 23.77%.
The industry rank for Abbott Laboratories's 3-1 Month Momentum % or its related term are showing as below:
MEX:ABT's 3-1 Month Momentum % is ranked better than 90.34% of 849
companies
in the Medical Devices & Instruments industry
Industry Median: 0.51
vs MEX:ABT: 23.77
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Abbott Laboratories 3-1 Month Momentum % Related Terms
MEX:ABT vs SYK, MDT, BSX: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Abbott Laboratories's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Abbott Laboratories's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (MEX:ABT) has a 3-1 Month Momentum % of 23.77% as of Sep. 22, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Abbott Laboratories and its competitors. According to the industry distribution chart, Abbott Laboratories ranks #82 out of 849 companies in the Medical Devices & Instruments industry, placing it in the top 9.7%.
Is Abbott Laboratories' 3-1 Month Momentum % too high?
Abbott Laboratories' current 3-1 Month Momentum % is 23.77%. The Medical Devices & Instruments industry median 3-1 Month Momentum % is 0.51. Abbott Laboratories' value of 23.77% is 4560.8% above this industry median. Based on the distribution chart, Abbott Laboratories ranks #82 out of 849 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Abbott Laboratories has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories' 3-1 Month Momentum % compare to SYK and MDT?
According to the Medical Devices & Instruments industry distribution chart, Abbott Laboratories ranks #82 out of 849 companies for 3-1 Month Momentum %. This places Abbott Laboratories in the top 10% of its industry — outperforming the majority of peers. The industry median 3-1 Month Momentum % is 0.51. Abbott Laboratories' value of 23.77% is 4560.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
The median 3-1 Month Momentum % among Medical Devices & Instruments companies is 0.51, based on 849 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories's current 3-1 Month Momentum % of 23.77% is 4560.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Abbott Laboratories and its competitors. For the Medical Devices & Instruments industry, the median 3-1 Month Momentum % is 0.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories's current 3-1 Month Momentum % is 23.77%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (MEX:ABT) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN2,290.92, compared to a current price of MXN1,760.66 — trading 23.1% below its estimated fair value. The current 3-1 Month Momentum % is 23.77% and 4560.8% above the Medical Devices & Instruments industry median of 0.51. Abbott Laboratories' overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Abbott Laboratories (MEX:ABT), the current 3-1 Month Momentum % is 23.77% as of Sep. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (MEX:ABT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories stock appears to be undervalued.
The current stock price of MXN1,760.66 is trading 23.1% below its estimated GF Value™ of MXN2,290.92.
GuruFocus considers Abbott Laboratories to be Modestly Undervalued.
Key valuation signals for MEX:ABT:
3-1 Month Momentum %: 23.77%
GF Value™: MXN2,290.92 vs. price of MXN1,760.66 (23.1% below fair value)
Industry Position: 4560.8% above the Medical Devices & Instruments median (#82 of 849)
No single metric tells the full story. See the MEX:ABT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott Laboratories is a diversified global healthcare company with four businesses. Medical Devices, its largest, leads in diabetes care with the FreeStyle Libre continuous glucose monitoring franchise, one of the fastest-growing medical device platforms ever, plus cardiovascular devices spanning heart valves, stents, electrophysiology, and heart pumps, and neuromodulation. Diagnostics provides laboratory, point-of-care, and rapid testing systems. Established Pharmaceuticals sells branded generic medicines exclusively in emerging markets. Nutrition includes Similac infant formula and Ensure and Glucerna adult nutrition brands. Abbott spun off its research-based pharmaceutical business as AbbVie in 2013. Founded in 1888 by Dr. Wallace Abbott and headquartered in Abbott Park, Illinois, the company sells in more than 160 countries, with a longstanding record of consecutive annual dividend increases.
83GF Score
Get the complete analysis for MEX:ABT
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ABT has been successfully added to your 
